Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: Modulation by peroxisome proliferator-activated receptor-gamma agonists

Cytokine

Volumn 50, Issue 3, 2010, Pages 260-267

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Fallahi, Poupak ^a   Ghiri, Emiliano ^a   Crescioli, Clara ^b   Romagnani, Paola ^b   Vitti, Paolo ^a   Serio, Mario ^b   Ferrannini, Ele ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

CXCL10; CXCL9; Interpheron alpha; Interpheron beta; Thyroid autoimmunity

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE;

ARTICLE; AUTOIMMUNITY; CELL CULTURE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG DOSE INCREASE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; THYROID DISEASE; THYROID FOLLICLE CELL;

CHEMOKINE CXCL10; CHEMOKINE CXCL9; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERON-GAMMA; INTERFERONS; PPAR GAMMA; THIAZOLIDINEDIONES; THYROID GLAND;

EID: 77952534161     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.01.009     Document Type: Article

References (44)

1. Baron S., Tyring S.K., Fleischmann W.R., Coppenhaver D.H., Niesel D.W., Klimpel G.R., et al. The interferons. Mechanisms of action and clinical applications. JAMA 1991, 266:1375-1383.
2. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
3. Bhakri H., Sriskandan K., Davis T., Pettingale K., Tee D. Recombinant gamma interferon and autoimmune thyroid disease. Lancet 1985, 2:457.
4. Prummel M.F., Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003, 13:547-551.
5. Okanoue T., Sakamoto S., Itoh Y., Minami M., Yasui K., Sakamoto M., et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996, 25:283-291.
6. Fattovich G., Giustina G., Favarato S., Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996, 24:38-47.
7. Koh L.K., Greenspan F.S., Yeo P.P. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997, 7:891-896.
8. Monzani F., Caraccio N., Dardano A., Ferrannini E. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 2004, 3:199-210.
9. Monzani F., Meucci G., Caraccio N., Saviozzi M., Casolaro A., Moscato G., et al. Discordant effect of IFN- 1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis. J Interf Cytok Res 2002, 22:773-781.
10. Chan W.B., Chow C.C., Cockram C.S. Interferon alpha treatment and endocrine disease. J R Soc Med 2003, 96:481-485.
11. Zlotnik A., Yoshle O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
12. Arenberg D.A., Polverini P.J., Kunkel S.L., Shanafelt A., Hesselgesser J., Horuk R., et al. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukocyte Biol 1997, 62:554-562.
13. Romagnani P., Rotondi M., Lazzeri E., Lasagni L., Francalanci M., Buonamano A., et al. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol 2002, 161:195-206.
14. Garcia-Lopez M.A., Sancho D., Sanchez-Madrid F., Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocr Metab 2001, 86:5008-5016.
15. Kemp E.H., Metcalfe R.A., Smith K.A., Woodroofe M.N., Watson P.F., Weetman A.P. Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf) 2003, 59:207-213.
16. Antonelli A., Rotondi M., Ferrari S.M., Fallahi P., Romagnani P., Franceschini S.S., et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocr Metab 2006, 91:614-620.
17. Antonelli A., Ferrari S.M., Fallahi P., Frascerra S., Santini E., Franceschini S.S., et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009, 94:1803-1809.
18. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Buonamano A., et al. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocr Metab 2004, 89:5496-5499.
19. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Paolicchi A., et al. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 2005, 152:171-177.
20. Proost P., Struyf S., Loos T., Gouwy M., Schutyser E., Conings R., et al. Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. Arthritis Res Ther 2006, 8:R107.
21. Aubry F., Habasque C., Satie A.P., Jégou B., Samson M. Expression and regulation of the CXC-chemokines, GRO/KC and IP-10/mob-1 in rat seminiferous tubules. Eur Cytokine Netw 2000, 11:690-698.
22. Veckman V., Miettinen M., Matikainen S., Lande R., Giacomini E., Coccia E.M., et al. Lactobacilli and streptococci induce inflammatory chemokine production in human macrophages that stimulates Th1 cell chemotaxis. J Leukocyte Biol 2003, 74:395-402.
23. Marx N., Mach F., Sauty A., Leung J.H., Sarafi M.N., Ransohoff R.M., et al. Peroxisome proliferator-activated receptor-activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000, 164:6503-6508.
24. Santini E., Fallahi P., Ferrari S.M., Masoni A., Antonelli A., Ferrannini E. Effect of PPAR- activation and inhibition on glucose-stimulated insulin release in INS-1e cells. Diabetes 2004, 53(Suppl. 3):S79-S83.
25. Jonasch E., Haluska F.G. Interferon in oncological practice. review of interferon biology, clinical applications, and toxicities. Oncologist 2001, 6:34-55.
26. Vial T., Descotes J. Immune-mediated side effects of cytokines in humans. Toxicology 1995, 105:31-57.
27. Yamazaki K., Kanaji Y., Shizume K., Yamakawa Y., Demura H., Kanaji Y., et al. Reversible inhibition by interferons and of 125I incorporation and thyroid hormone release by human thyroid follicles in vitro. J Clin Endocr Metab 1993, 77:1439-1441.
28. Roti E., Minelli R., Giuberti T., Marchelli S., Schianchi C., Gardini E., et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996, 101:482-487.
29. Caraccio N., Giannini R., Cuccato S., Faviana P., Berti P., Galleri D., et al. Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocr Metab 2005, 90:1156-1162.
30. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Barani L., et al. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf) 2006, 64:189-195.
31. Antonelli A., Fallahi P., Rotondi M., Ferrari S.M., Serio M., Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Brit J Surg 2006, 93:1226-1231.
32. Antonelli A., Rotondi M., Fallahi P., Grosso M., Boni G., Ferrari S.M., et al. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocr Metab 2007, 92:1485-1490.
33. Antonelli A., Fallahi P., Rotondi M., Ferrari S.M., Romagnani P., Grosso M., et al. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006, 154:651-658.
34. Tsubota A., Hirose Y., Izumi N., Kumada H. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 2003, 55:360-367.
35. Di Girolamo G., Kauffman M.A., González E., Papouchado M., Ramírez A., Keller G., et al. Bioequivalence of two subcutaneous pharmaceutical products of interferon beta la. Arzneimittelforschung 2008, 58:193-198.
36. Martin A.P., Coronel E.C., Sano G., Chen S.C., Vassileva G., Canasto-Chibuque C., et al. A novel model for lymphocytic infiltration of the thyroid gland generated by transgenic expression of the CC chemokine CCL21. J Immunol 2004, 173:4791-4798.
37. Caturegli P., Hejazi M., Suzuki K., Dohan O., Carrasco N., Kohn L.D., et al. Hypothyroidism in transgenic mice expressing in the thyroid. Proc Natl Acad Sci USA 2000, 97:1719-1724.
38. Kung A.W., Jones B.M., Lai C.L. Effects of interferon-gamma therapy on thyroid function, T-lymphocyte subpopulations and induction of autoantibodies. J Clin Endocrinol Metab 1990, 71(5):1230-1234.
39. Wills R.J. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990, 19(5):390-399.
40. Gosset P., Charbonnier A.S., Delerive P., Fontaine J., Staels B., Pestel J., et al. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol 2001, 31:2857-2865.
41. Schaefer K.L., Denevich S., Ma C., Cooley S.R., Nakajima A., Wada K., et al. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 2005, 11:244-252.
42. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999, 104:383-389.
43. Lombardi A., Cantini G., Piscitelli E., Gelmini S., Francalanci M., Mello T., et al. A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Arterioscl Throm Vas 2008, 28:718-724.
44. Lehmann G.M., Garcia-Bates T.M., Smith T.J., Feldon S.E., Phipps R.P. Regulation of lymphocyte function by PPARgamma: relevance to thyroid eye disease-related inflammation. PPAR Res 2008, 2008:895901.